- Home
- ZYME
ZYME
Zymeworks Inc.
as 04-18-2025 1:45pm EST
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | MIDDLETOWN |
| Market Cap: | 761.2M | IPO Year: | 2017 |
| Target Price: | $19.50 | AVG Volume (30 days): | 833.8K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.97 - $17.70 | Next Earning Date: | 05-08-2025 |
| Revenue: | $76,304,000 | Revenue Growth: | 0.38% |
| Revenue Growth (this year): | 26.29% | Revenue Growth (next year): | 75.78% |
Stock Insider Trading Activity of Zymeworks Inc. (ZYME)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | ZYME | Director10% Owner | Apr 3 '25 | Buy | $11.50 | 317,208 | $3,623,970.36 | 17,503,336 | |
| EcoR1 Capital, LLC | ZYME | Director10% Owner | Mar 31 '25 | Buy | $11.73 | 127,415 | $1,497,322.33 | 17,503,336 | |
| EcoR1 Capital, LLC | ZYME | Director10% Owner | Mar 25 '25 | Buy | $12.57 | 97,349 | $1,227,309.18 | 17,503,336 | |
| EcoR1 Capital, LLC | ZYME | Director10% Owner | Mar 20 '25 | Buy | $12.93 | 127,198 | $1,643,247.98 | 17,503,336 | |
| EcoR1 Capital, LLC | ZYME | Director10% Owner | Mar 17 '25 | Buy | $12.51 | 228,463 | $2,866,552.72 | 17,503,336 | |
| EcoR1 Capital, LLC | ZYME | Director10% Owner | Mar 11 '25 | Buy | $12.08 | 1,081,980 | $13,120,914.17 | 17,503,336 |
Latest Zymeworks Inc. News
ZYME Breaking Stock News: Dive into ZYME Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
GlobeNewswire
24 days ago
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
25 days ago
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Simply Wall St.
a month ago
Analysts Just Shipped A Captivating Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates
GlobeNewswire
a month ago
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
GuruFocus.com
2 months ago
Zymeworks Inc (ZYME) Q4 2024 Earnings Report Preview: What To Look For
GlobeNewswire
2 months ago
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
GlobeNewswire
2 months ago
Zymeworks Announces Participation in Upcoming Investor Conferences
Compare ZYME vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZYME Zymeworks Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.